Overview

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

Status:
Terminated
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This research study is a Phase II clinical trial, which evaluates a combination of drugs, FOLFIRINOX and Gemcitabine/Nab-Paclitaxel, in the management of participants with resectable pancreatic cancer prior to surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Treatments:
Albumin-Bound Paclitaxel
Capecitabine
Folfirinox
Gemcitabine
Paclitaxel